The clinical relevance of tumor RAS/TP53 dual mutation in early and metastatic colorectal cancer (CRC).

Seligmann, JF, Domingo, E, Fisher, D et al. (17 more authors) (2022) The clinical relevance of tumor RAS/TP53 dual mutation in early and metastatic colorectal cancer (CRC). In: 2022 ASCO Annual Meeting, 03-07 Jun 2022, Chicago, Il, USA and Online.

Metadata

Item Type: Conference or Workshop Item
Authors/Creators:
Dates:
  • Published: 1 June 2022
Institution: The University of Leeds
Funding Information:
Funder
Grant number
Cancer Research UK Supplier No: 138573
C7852/A19772
Leeds Teaching Hospitals Charitable Foundation
Fund No IT01
Cancer Research UK Supplier No: 138573
RCS REF 08-0843 SUBCONTR
Cancer Research UK Supplier No: 138573
C6003/A7367
Leeds Hospitals Charity
1T01-A321
Leeds Teaching Hospitals Charitable Foundation
4616
Cancer Research UK Supplier No: 138573
C6003/A15546
Amgen Limited ***USE 819922***
NOT GIVEN
MRC (Medical Research Council)
2012-005111-12
NIHR National Inst Health Research
2012-005111-12
Depositing User: Symplectic Publications
Date Deposited: 21 Nov 2022 13:57
Last Modified: 21 Nov 2022 13:57
Status: Published
Identification Number: 10.1200/JCO.2022.40.16_suppl.3540
Related URLs:
Open Archives Initiative ID (OAI ID):

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics